Copy Link Print Information

ODN 1826

(別名: CpG 1826)
12 Cited Publications
カスタマーレビュー

Based on 12 publication(s) in Google Scholar

ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度: 99.51%
  • CAS 番号: 202668-42-6
  • 分子量:6364.10
  • 保管条件:

    -20°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • ODN 1826 Chemical Structure
    ODN 1826 構造式
  • Experimental Validation Results for ODN 1826
  • Experimental Validation Results for ODN 1826
  • Experimental Validation Results for ODN 1826
  • Experimental Validation Results for ODN 1826
  • Experimental Validation Results for ODN 1826
  • Experimental Validation Results for ODN 1826
CAS 番号: 202668-42-6
容量
価格（税別）
在庫状況
数量
Amount: USD 0.00
Please select quantity
or
or

* アイテムを追加する前、数量をご選択ください

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of ODN 1826:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
最寄りの代理店をお探しください Your local distributor: Hycultec GmbHHycultec
  • 生物活性
  • 化学情報
  • 溶剤 & 溶解度
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs
Top Publications Citing

Use of MCE Products

MedChemExpress（MCE）の使用を引用している文献 ODN 1826

More
Customer Validation & Images
Cell Proliferation/Viability AssayRT-PCRHistological Imaging/StainingApoptosis AnalysisWB
  • RT-PCR
  • Cell Proliferation/Viability Assay
  • Histological Imaging/Staining
  • Cell Proliferation/Viability Assay
  • Apoptosis Analysis
  • WB

Toll-like Receptor (TLR) アイソフォーム固有の製品をすべて表示

More

NO Synthase アイソフォーム固有の製品をすべて表示

More
Keywords
MOQ
Minimum order quantity
100 mg

お問い合わせ 在庫あり

Other size
お問い合わせ
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress ログイン
Register
Sign in to MedChemExpress
新規会員登録

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • ODN 1826 Chemical Structure
    ODN 1826 Chemical Structure DNA, d(P-thio)(T-C-C-A-T-G-A-C-G-T-T-C-C-T-G-A-C-G-T-T)
    1/16
  • 1/16

    ODN 1826 purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Sep 1:e02375. [Abstract]

    Customer Validation
     ODN 1826 (CpG, 500 ng per well; 24 h) significantly promoted the repolarization of M2-typed bone marrow-derived cells (BMDM), which stood for tumor-associated macrophages (TAM), with a significant increase of M1 (iNOS) and a decrease of M2 markers (Fizz1 and Mrc1).

  • 1/16

    ODN 1826 purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Nov 1:380:123930. [Abstract]

    Customer Validation
     Cytotoxicity analysis of DC 2.4 cells treated with DNA-OprF/PcrV + CpG (ODN 1826) for 24 h. CpG was functionally integrated with the DNA vaccine via physical mixing. Specifically, 10 μg of pVAX1-OprF, 10 μg of pVAX1-PcrV, and 10 μg of CpG ODN were vortex-mixed in 150 μl of 1640 medium, followed by the addition of 60 μl of transfection reagent (mass-to-volume ratio = 1:2). The mixture was incubated at room temperature for 30 min to form transfection complexes, sterilized by passage through a 0.22 μm filter, and used immediately.

  • 1/16

    ODN 1826 purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Nov 1:380:123930. [Abstract]

    Customer Validation
     ODN 1826 (CpG, 0.1 μg/μL; s.c.; 200 μL injected every 2 weeks for a total of three times).
    HE-stained image of pathological sections of the heart, liver, lung, and kidney after immunization (100×). Scale bar = 50 μm. These results revealed no obvious tissue pathological changes or inflammatory cell infiltration in the four treatment groups, including the DNA-OprF/PcrV + CpG group.

  • 1/16

    ODN 1826 purchased from MedChemExpress. Usage Cited in: Neurochem Res. 2025 Sep 5;50(5):288. [Abstract]

    Customer Validation
     ODN 1826 (CpG) regulate astrocyte cell viability and TLR9/NF-κB pathway activation. Human astrocytes were treated with varying concentrations of CpG oligodeoxynucleotides (0, 100, 1000, and 5000 ng/mL) for 24 h. Cell viability was assessed using CCK-8 assay.

  • 1/16

    ODN 1826 purchased from MedChemExpress. Usage Cited in: Neurochem Res. 2025 Sep 5;50(5):288. [Abstract]

    Customer Validation
     ODN 1826 (CpG) regulate astrocyte cell viability and TLR9/NF-κB pathway activation. Human astrocytes were treated with varying concentrations of CpG oligodeoxynucleotides (0, 100, 1000, and 5000 ng/mL) for 24 h. Apoptosis rates were determined by flow cytometry analysis using Annexin V-FITC and propidium iodide staining.

  • 1/16

    ODN 1826 purchased from MedChemExpress. Usage Cited in: Neurochem Res. 2025 Sep 5;50(5):288. [Abstract]

    Customer Validation
     ODN 1826 (CpG) regulate astrocyte cell viability and TLR9/NF-κB pathway activation. Human astrocytes were treated with varying concentrations of CpG oligodeoxynucleotides (0, 100, 1000, and 5000 ng/mL) for 24 h. Protein expression levels of TLR9, total NF-κB, and phosphorylated NF-κB (p-NF-κB) were analyzed by Western blot with GAPDH as loading control.

  • DNA, d(P-thio)(T-C-C-A-T-G-A-C-G-T-T-C-C-T-G-A-C-G-T-T)